Gastric cancer with positive peritoneal cytology: survival benefit after induction chemotherapy and conversion to negative peritoneal cytology

Table 1 Patient characteristics

	Negative, n = 125	Converted negative, n = 9	Not converted, n = 5	Peritoneal metastasis, n = 33	p
Age (years)	61 ± 13	54 ± 9	64 ± 9	53 ± 15	0.016
Gender m/f	88 (70%)/7 (30%)	4 (44%)/5 (56%)	3 (60%)/2 (40%)	21 (64%)/2 (36%)	0.390
Tumor location
AEG	61 (49%)	5 (55%)	5 (100%)	10 (30%)	0.021
Gastric	64 (51%)	4 (45%)	0	23 (70%)
Chemotherapy
FLOT	62 (50%)	9 (100%)	2 (40%)	19 (58%)	>0.001
ECF	13 (10%)	0	3 (60%)	4 (12%)
Others	0	0	0	3 (9%)
No chemotherapy	50 (40%)	0	0	7 (21%)
pT or ypT
T0	7 (5%)	1 (11%)	0	NA	0.141
T1	36 (29%)	0	0
T2	20 (16%)	1 (11%)	0
T3	51 (41%)	7 (78%)	4 (80%)
T4	11 (9%)	0	1 (20%)
Positive lymph nodes	64 (51%)	5 (55%)	5 (100%)	NA	0.109
Mean retrieved LN	42 ± 20	56 ± 11	36 ± 11	NA	0.105
Grading^a
G1	3 (3%)	0	0	0	0.772
G2	25 (26%)	1 (11%)	1 (20%)	2 (13%)
G3	67 (71%)	8 (89%)	4 (80%)	13 (87%)
Lauren type^a
Intestinal	64 (61%)	4 (45%)	4 (80%)	6 (22%)	0.002
Diffuse	41 (39%)	5 (55%)	1 (20%)	21 (78%)

Patient characteristics are summarized according to the presence or absence of peritoneal disease during staging laparoscopy. While n = 125 patients had no peritoneal disease, n = 9 converted to CY− and n = 5 remained CY+ after neoadjuvant chemotherapy. Macroscopic peritoneal metastasis was present in n = 33 patients
AEG adenocarcinoma of the esophago-gastric junction, LN lymph nodes, NA not available
^aThe data for some patients is missing. p-values are based on the chi-square test and Fisher’s exact test for categorical variables and ANOVA for continuous variables

ISSN: 1477-7819